rozanolixizumab-noli , a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive was recently approved by the fda under the name of RYTIGGO. (6.26.2023). Congrats to all the members of the researchanddevelopment team who contributed to this achievement!
We at Magellan Biologics & Consulting support the scientific communityworking on R&D projects at #
discovery stage with transient proteinexpression solutions in mammalian cells.
Discover how on:
https://lnkd.in/eJTbB_-5
